Last reviewed · How we verify
desmopressin tablet
Desmopressin is a synthetic vasopressin analog that binds to V2 receptors on kidney collecting duct cells to increase water reabsorption and reduce urine output.
Desmopressin is a synthetic vasopressin analog that binds to V2 receptors on kidney collecting duct cells to increase water reabsorption and reduce urine output. Used for Central diabetes insipidus, Nocturnal enuresis (bedwetting), Polycystic kidney disease (adjunctive).
At a glance
| Generic name | desmopressin tablet |
|---|---|
| Also known as | DDAVP |
| Sponsor | University Hospital, Ghent |
| Drug class | Vasopressin analog; antidiuretic agent |
| Target | V2 vasopressin receptor |
| Modality | Small molecule |
| Therapeutic area | Endocrinology; Urology |
| Phase | FDA-approved |
Mechanism of action
Desmopressin mimics the action of endogenous antidiuretic hormone (ADH/vasopressin) by selectively activating V2 receptors in the renal collecting ducts, promoting aquaporin-2 water channel insertion and increasing water reabsorption. This reduces urine volume and increases urine osmolality. It has minimal vasopressor activity compared to native vasopressin due to its selectivity for V2 over V1 receptors.
Approved indications
- Central diabetes insipidus
- Nocturnal enuresis (bedwetting)
- Polycystic kidney disease (adjunctive)
- Von Willebrand disease and mild hemophilia A
Common side effects
- Hyponatremia (water intoxication)
- Headache
- Nausea
- Abdominal pain
- Facial flushing
Key clinical trials
- Ginkgo Biloba vs Desmopressin in Treatment of Children With Monosymptomatic Nocturnal Enuresis (NA)
- Uroflowmetry and Nocturnal Enuresis
- Ginko Biloba Versus Desmopressin in Treatment of Children With Monosymptomatic Nocturnal Enuresis (NA)
- Specified Drug Use-results Survey (Long-term Use) on MINIRINMELT® OD Tablet (Nocturia)
- Desmopressin for Bedwetting in Children With SCD (PHASE4)
- Selective Serotonin Reuptake Inhibitors, Fluoxetine Versus the Standard Oral Desmopressin for Management of Mono-symptomatic Nocturnal Enuresis. (NA)
- Mirabegron 25 mg for Treatment of Primary Nocturnal Enuresis (NA)
- Desmopressin as a Therapy for Bedwetting in Children With Sickle Cell Disease
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- desmopressin tablet CI brief — competitive landscape report
- desmopressin tablet updates RSS · CI watch RSS
- University Hospital, Ghent portfolio CI